Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

HeartBeam Announces FDA Submission Of HeartBeam AIMI Product

By Benzinga Newsdesk
August 16, 8:42 AM
Submission Seeks Approval for the Company's Proprietary ECG Technology to Aid in Diagnosis of Heart Attack in $500 million Total Addressable Market 18+ million People in the US have Coronary Artery DiseaseSubmission Seeks Approval for the Company's Proprietary ECG Technology to Aid in Diagnosis of Heart Attack in $500 million Total Addressable Market

BEAT

Read More
2 minute read

AstraZeneca Announced Lynparza in Combination with Abiraterone Granted Priority Review in the US for Patients with Metastatic Castration-resistant Prostate Cancer

By Charles Gross
August 16, 4:52 AM
AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialised by AstraZeneca and MSD.

AZN